+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 33 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
O

Actively Recruiting

Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.

Age: 50Years +All GendersPhase 3
566 locations
R

Actively Recruiting

This trial evaluates the combination of Navlimetostat BMS-986504, pembrolizumab, and chemotherapy compared to placebo with pembrolizumab and chemotherapy in adults with first-line metastatic non-small cell lung cancer having homozygous MTAP deletion. The study is a randomized, double-blind Phase 23 trial sponsored by Bristol-Myers Squibb, aiming to understand treatment benefits in this specific patient group. Participants must have measurable metastatic NSCLC, no prior systemic therapy for metastatic disease, and meet performance status criteria. Participants receive either Navlimetostat plus pembrolizumab and chemotherapy or placebo plus pembrolizumab and chemotherapy. Chemotherapy may include drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel, given on specified days at specified doses. Treatment is administered in the first-line metastatic setting, with detailed dosing and combinations determined by study protocols. Randomization assigns participants to one of multiple arms to compare the investigational combination against placebo. Throughout the study, participants are monitored for progression-free survival up to 2 years and 5 years, overall survival up to 5 years, as well as response rates and safety outcomes including adverse events and laboratory abnormalities. Assessments follow RECIST v1.1 criteria with independent and investigator reviews. Safety monitoring includes tracking serious adverse events and treatment-related side effects up to 90 days after treatment ends. The study duration extends to the primary completion date in August 2031, with ongoing evaluations for up to 5 years post-treatment.

Age: 18Years +All GendersPhase 2Phase 3
321 locations
R

Actively Recruiting

Researchers are evaluating the effects of PKN605, an oral medication, in adults with atrial fibrillation to see if it reduces the time spent in atrial fibrillation. This randomized, placebo-controlled, double-blind study aims to assess the treatments efficacy, safety, tolerability, and how the drug behaves in the body. The study is sponsored by Novartis Pharmaceuticals and focuses on participants with a history of atrial fibrillation. Participants will first undergo a screening period lasting up to 90 days to confirm eligibility. Once enrolled, they will be randomly assigned to receive either a lower or higher dose of oral PKN605 or a matching placebo. The treatment phase will last 24 weeks, with monthly clinic visits. Atrial fibrillation will be monitored throughout the study using various ECG devices. After treatment ends, there will be a final safety follow-up visit about one month later. During the study, participants will have regular assessments including ECG patch monitoring to measure atrial fibrillation burden, blood tests for drug levels, and other safety evaluations. Researchers will measure the time spent in atrial fibrillation and the time to first recurrence of atrial fibrillation after treatment begins. The total participation time includes screening, 24 weeks of treatment, and a safety follow-up visit approximately one month after treatment completion.

Age: 18Years +All GendersPhase 2
40 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying the role of amniotic fluid in the development and microbial colonization of the intestinal tract in extremely preterm infants born between 24 and 27 weeks of gestation. The study aims to understand how changes in amniotic fluid composition relate to conditions like chorioamnionitis and fetal growth restriction, and how these changes might affect neonatal outcomes such as necrotizing enterocolitis and sepsis. This observational study involves detailed profiling of amniotic fluid and early gut microbiota to identify patterns linked to these risks. The study collects about 5 mL of amniotic fluid from mothers delivering extremely preterm infants either vaginally or via cesarean section. It also includes a reference group of pregnancies at various gestational ages, from early midtrimester to full term. The collected fluid is analyzed using advanced biomedical techniques for microbial and metabolic profiles. Neonatal fecal samples will also be studied at days 0, 7, 14, 21, and 28 to examine early gut colonization. Participants will be involved through the collection of amniotic fluid at birth and neonatal stool samples over the first month of life. Researchers will monitor and analyze amniotic fluid characteristics in relation to chorioamnionitis, fetal growth restriction, and neonatal health outcomes including necrotizing enterocolitis and sepsis. The study aims to improve understanding of gastrointestinal development in preterm infants and identify high-risk cases, potentially guiding future interventions. The total study duration spans from birth through the first 28 postnatal days for microbiota monitoring.

Age: 16Years +FEMALE
2 locations
U

Actively Recruiting

Researchers are studying individuals with a bleeding disorder of unknown cause BDUC, a condition where people experience increased bleeding but standard lab tests do not identify a specific cause. This study aims to better understand the reasons behind unexplained bleeding in BDUC, how it affects daily life and health-related quality of life, and how care for these patients can be improved. The study is observational and involves multiple centers in the Netherlands. Participants aged 12 and older with increased bleeding symptoms who remain undiagnosed after standard coagulation testing will be enrolled. They will undergo advanced blood testing for hemostasis and genetic analysis. Participants will also complete questionnaires assessing bleeding symptoms and quality of life. The study will follow participants for up to 10 years to observe changes over time and to evaluate healthcare delivery and patient outcomes. During the study, participants will have blood samples taken for detailed laboratory analyses and will provide information through validated questionnaires. Researchers will assess bleeding symptoms, bleeding severity, physical activity, patient activation, and satisfaction with care, among other outcomes. The study also includes evaluations of diagnostic delays and responses to hemostatic challenges. This long-term observation will help identify subgroups within BDUC and develop improved care pathways based on collected clinical, laboratory, and patient-reported data.

Age: 12Years +All Genders
8 locations
T

Actively Recruiting

Healthy Volunteer

This trial investigates the effectiveness of vaginal cerclage compared to standard treatment in women with twin pregnancies who have a short cervix or cervical dilatation in midpregnancy. The study focuses on preventing extreme preterm birth before 28 weeks of gestation, a serious concern due to high rates of perinatal death in this group. The research aims to provide evidence on whether cerclage can reduce early births and improve outcomes for babies and families. Participants will be randomly assigned to receive either a vaginal cerclage or standard care without cerclage. The cerclage procedure involves placing an unabsorbable suture around the cervix under anesthesia to strengthen and close it, aiming to prevent cervical insufficiency. The comparison group will follow current Dutch guidelines, which do not include cerclage for this condition. During the study, participants will be monitored for preterm birth rates and various maternal and neonatal health outcomes up to three months after birth. Assessments include gestational age at delivery, days on ventilation and in neonatal intensive care, maternal quality of life, and adverse events. The primary measure is the rate of extreme preterm birth before 28 weeks. The trial will continue until December 2028, with ongoing evaluation of both short-term and longer-term effects.

Age: 16Years +FEMALEPhase Not Applicable
13 locations
S

Actively Recruiting

Researchers are studying patients with non-metastatic stage II colon cancer who are part of the Dutch ColoRectal Cancer cohort PLCRC and who consented to additional blood samples. The study aims to evaluate how many patients with detectable circulating tumor DNA ctDNA after surgery begin adjuvant chemotherapy. This observational and interventional trial includes patients who do not have a standard indication for chemotherapy and involves a randomized design to compare ctDNA-guided treatment with standard care. Patients are randomly assigned to one of two groups the ctDNA-based treatment group or the standard care group. In the ctDNA group, blood samples taken after surgery are analyzed for ctDNA. Those with detectable ctDNA are offered 3 months of adjuvant chemotherapy using CAPOX a combination of fluoropyrimidine and oxaliplatin. Patients without detectable ctDNA receive routine follow-up care. The standard care group receives routine follow-up without knowledge of their ctDNA results. Participants will have blood collected before surgery, after surgery, and during follow-up. Researchers will monitor who starts chemotherapy within 8 to 12 weeks after surgery and will track recurrence rates, disease-free survival, overall survival, time to recurrence, quality of life, and cost-effectiveness over several years. Follow-up assessments occur up to 10 years, allowing detailed long-term evaluation of treatment impact and patient outcomes.

Age: 18Years +All GendersPhase Not Applicable
29 locations

1-10 of 33

1